Sovateltide in cerebral ischaemic stroke: a profile of its use
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and conflict of interest S. Fung and Y. Y. Syed are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Abstract
Sovateltide (TyvalziTM), a first-in-class selective endothelin B receptor agonist, is a valuable new therapy for the treatment of cerebral ischaemic stroke. It promotes neurovascular remodelling, increases cerebral blood flow, has anti-apoptotic activity, protects neural mitochondria, and enhances mitochondrial biogenesis. In a randomized, placebo-controlled phase 3 study in patients with cerebral ischaemic stroke, the addition of sovateltide within 24 h of symptom onset to standard of care treatment provided statistically significant and clinically meaningful improvement in neurological outcomes 90 days post-randomization. Additionally, sovateltide was generally well tolerated.
© Springer Nature Switzerland AG 2024
